Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462447 | 0.74 | CYP1A2 (0.66) | CYP1A2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31538813 | 0.73 | ALDH1A1 (0.54) | CYP1A2ALDH1A1MEN1KMT2ACYP2D6 | |
| SCHEMBL27433410 | 0.73 | ALDH1A1 (0.54) | CYP1A2ALDH1A1MEN1KMT2ACYP2D6 | |
| Hydrochloric Acid SCHEMBL3647675 | 0.72 | ALDH1A1 (0.64) | CYP1A2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4503545 | 0.71 | LMNA (0.43) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL8172224 | 0.71 | LMNA (0.59) | CYP1A2ALDH1A1SMN1; SMN2KMT2ACYP2D6 | |
| SCHEMBL5825618 | 0.71 | KMT2A (0.54) | CYP1A2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4504332 | 0.70 | KDM4E (0.43) | ALDH1A1SMN1; SMN2CYSLTR2CYSLTR1MEN1 | |
| SCHEMBL4509859 | 0.70 | LMNA (0.42) | CYP1A2ALDH1A1SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL4427773 | 0.69 | L3MBTL1 (0.60) | CYP1A2ALDH1A1MEN1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | JINA PHARMACEUTICALS, INC. | 2021-06-17 | — | — | US | disclosed |
| US-10376479-B2 | Endoxifen compositions and methods | JINA PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190231687-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | JINA PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-2101731-B1 | ENDOXIFEN FOR USE IN THE TREATMENT OF CANCER | JINA PHARMACEUTICALS INC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20160346230-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9333190-B2 | Endoxifen compositions and methods | JINA PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20120164075-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2432462-A2 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | Jina Pharmaceuticals Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135703-A2 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100112041-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20090291134-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| EP-2101731-A2 | ENDOXIFEN METHODS AND COMPOSITIONS | Jina Pharmaceuticals Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008070463-A9 | ENDOXIFEN METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008070463-A2 | ENDOXIFEN METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112041-A1 | Endoxifen Compositions And Methods | CYP46A1, PLA2G2F, VDR | CYP1A2 401/4885ALDH1A1 4041/4885SMN1; SMN2 4721/4885 |
| US-20160346230-A1 | Endoxifen Compositions And Methods | CYP46A1, PLA2G2F, VDR | CYP1A2 401/4885ALDH1A1 4041/4885SMN1; SMN2 4721/4885 |
| US-20090291134-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | NLN, BDNF, LITAF | CYP1A2 686/4885ALDH1A1 2971/4885SMN1; SMN2 187/4885 |
| US-10376479-B2 | Endoxifen compositions and methods | CYP46A1, PLA2G2F, VDR | CYP1A2 401/4885ALDH1A1 4041/4885SMN1; SMN2 4721/4885 |
| US-20120164075-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | ENPP2, ERAL1, LITAF | CYP1A2 696/4885ALDH1A1 3680/4885SMN1; SMN2 1027/4885 |
| US-20190231687-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | NLN, BDNF, LITAF | CYP1A2 686/4885ALDH1A1 2971/4885SMN1; SMN2 187/4885 |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | EEF2K, LITAF, RAPGEF3 | CYP1A2 3363/4885ALDH1A1 4639/4885SMN1; SMN2 811/4885 |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | EEF2K, LITAF, RAPGEF3 | CYP1A2 3363/4885ALDH1A1 4639/4885SMN1; SMN2 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.